Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country.

alcohol discordant familial risks gallbladder cancer hepatocellular carcinoma risk factors spouse correlation

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
12 Apr 2022
Historique:
received: 07 02 2022
revised: 30 03 2022
accepted: 06 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

We used the Swedish Cancer Registry data to address familial risks for concordant (same) and discordant (different) hepatobiliary cancers, including their associations with any other cancers and with known risk factors. Risks were also assessed between spouses. The analysis covered Swedish families and their cancers between years 1958 and 2018. Adjusted familial risks were expressed as standardized incidence ratios (SIRs). Familial SIRs for concordant hepatocellular carcinoma (HCC) were 2.60, and for gallbladder cancer they were at the same level (2.76). Familial risk was also found for intrahepatic bile duct cancer and for female extrahepatic bile duct cancer. HCC was associated with lung and cervical cancers; extrahepatic bile duct and ampullary cancers were associated with colon and pancreatic cancers, suggesting Lynch syndrome. Among spouses, hepatobiliary cancer was associated with HCC, stomach, pancreatic, cervical and upper aerodigestive tract cancers. Among risk factors, family members diagnosed with alcohol-related disease showed association with HCC. The observed familial risks for hepatobiliary cancers were relatively high, and considering the poor prognosis of these cancers, prevention is of the utmost importance and should focus on moderation of alcohol consumption, vaccination/treatment of hepatitis viral infections and avoidance of overweight and other risk factors of type 2 diabetes.

Identifiants

pubmed: 35454845
pii: cancers14081938
doi: 10.3390/cancers14081938
pmc: PMC9030935
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : European Commission
ID : 856620

Références

Mutat Res Rev Mutat Res. 2018 Oct - Dec;778:61-71
pubmed: 30454684
Cancers (Basel). 2021 Aug 30;13(17):
pubmed: 34503195
Genet Med. 2020 Jan;22(1):15-25
pubmed: 31337882
Eur J Cancer Prev. 2002 Oct;11(5):433-8
pubmed: 12394240
Clin Gastroenterol Hepatol. 2014 Jun;12(6):1038-45.e7
pubmed: 24246767
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Theranostics. 2018 Feb 12;8(6):1740-1751
pubmed: 29556353
BMJ Open Gastroenterol. 2017 Dec 29;4(1):e000188
pubmed: 29333277
Eur J Cancer Prev. 2003 Oct;12(5):355-8
pubmed: 14512798
Gut. 2003 Apr;52(4):592-6
pubmed: 12631675
BJS Open. 2020 Feb;4(1):109-117
pubmed: 32011814
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
Clin Epidemiol. 2021 Aug 04;13:683-691
pubmed: 34377034
Oncologist. 2017 Jul;22(7):804-810
pubmed: 28487467
Int J Cancer. 2014 Apr 15;134(8):1899-906
pubmed: 24590453
Medicine (Baltimore). 2020 Jan;99(5):e19076
pubmed: 32000458
IARC Monogr Eval Carcinog Risks Hum. 2001;78(Pt 2):1-559
pubmed: 11421248
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):605-614
pubmed: 29579789
Cancer. 2020 Nov 1;126(21):4788-4799
pubmed: 32857459
Int J Cancer. 2014 Oct 1;135(7):1605-14
pubmed: 24535817
Lancet Oncol. 2009 May;10(5):481-8
pubmed: 19356978
Int J Cancer. 2010 May 15;126(10):2259-67
pubmed: 19642094
Int J Cancer. 2019 Feb 15;144(4):707-717
pubmed: 30155920
Int J Cancer. 2015 Aug 15;137(4):903-10
pubmed: 25604005
Lancet Oncol. 2017 Jun;18(6):e296
pubmed: 28593851
Gut. 2018 Jul;67(7):1306-1316
pubmed: 28754778
Hepatology. 2012 May;55(5):1416-25
pubmed: 22095619
Clin Exp Hepatol. 2019 May;5(2):93-102
pubmed: 31501784
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Cancer Med. 2017 May;6(5):1135-1140
pubmed: 28374973
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
J Natl Cancer Inst. 2019 Dec 1;111(12):1263-1278
pubmed: 31127946
Cancer. 2019 May 1;125(9):1441-1448
pubmed: 30620386
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
J Med Virol. 2014 Jan;86(1):18-22
pubmed: 24038002
J Natl Cancer Inst. 2019 Nov 1;111(11):1142-1151
pubmed: 31168582

Auteurs

Kari Hemminki (K)

Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605 Pilsen, Czech Republic.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany.
Center for Primary Health Care Research, Lund University, 205 02 Malmö, Sweden.

Kristina Sundquist (K)

Center for Primary Health Care Research, Lund University, 205 02 Malmö, Sweden.
Department of Family Medicine and Community Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Center for Community-Based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane 693-8501, Japan.

Jan Sundquist (J)

Center for Primary Health Care Research, Lund University, 205 02 Malmö, Sweden.
Department of Family Medicine and Community Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Center for Community-Based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane 693-8501, Japan.

Asta Försti (A)

Center for Primary Health Care Research, Lund University, 205 02 Malmö, Sweden.
Hopp Children's Cancer Center (KiTZ), D-69120 Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), D-69120 Heidelberg, Germany.

Vaclav Liska (V)

Department of Surgery, School of Medicine in Pilsen, University Hospital, Charles University, 30605 Pilsen, Czech Republic.
Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605 Pilsen, Czech Republic.

Akseli Hemminki (A)

Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, 00290 Helsinki, Finland.
Comprehensive Cancer Center, Helsinki University Hospital, 00290 Helsinki, Finland.

Xinjun Li (X)

Center for Primary Health Care Research, Lund University, 205 02 Malmö, Sweden.

Classifications MeSH